Oxidative stress in patients with cardiovascular disease and chronic renal failure

Free Radical Research

Volumn 47, Issue 5, 2013, Pages 346-356

  Popolo, A ^a   Autore, G ^a   Pinto, A ^a   Marzocco, S ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Cardiovascular disease; Chronic renal failure; Oxidative stress; ROS

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ASCORBIC ACID; CATALASE; DIMETHYLTHIOUREA; GLUTATHIONE; MONOCYTE CHEMOTACTIC PROTEIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBUCOL; PROPIONYLCARNITINE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN;

ACUTE HEART INFARCTION; ANTIOXIDANT ACTIVITY; AORTA VALVE STENOSIS; ATHEROSCLEROSIS; BRAIN EDEMA; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; HEART FAILURE; HEMOCHROMATOSIS; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PULMONARY HYPERTENSION; REVIEW; UROLITHIASIS; WILSON DISEASE;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84876231789     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2013.779373     Document Type: Review

References (121)

1. Harman D . Aging: A theory based on free radical and radiation chemistry . J Gerontol 1956; 11 : 298-300.
2. Sugamura K, Keaney JF Jr . Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2011; 51: 978- 992
3. Mozaff arian D, Wilson PW, Kannel WB . Beyond established and novel risk factors lifestyle risk factors for cardiovascular disease . Circul 2008; 117 : 3031-3038.
4. US Renal Data System, USRDS . " Atlas of end-stage renal disease in the United States, " Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, 2009.
5. Manjunath G, Tighiouart H, Coresh J . Level of kidney function as a risk factor for cardiovascular outcomes in the elderly . Kidney Int, 2003; 63 : 1121-1129.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization . New Engl J Med 2004; 351 : 1296-1370.
7. Hambali Z, Ahmad Z, Arab S, Khazaai H . Oxidative stress and its association with cardiovascular disease in chronic renal failure patients. Indian J Nephrol 2003; 21: 21- 25.
8. Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D . Cardiovascular disease and mortality in a community- based cohort with mild renal insuffi ciency . Kidney Int 1999; 56 : 2214-2219.
9. Rhee SG . Redox signaling: Hydrogen peroxide as intracellular messenger . Exp Mol Med 1999; 31 : 53-59.
10. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C . Oxidative stress in end-stage renal disease: An emerging threat to patient outcome . Nephrol Dial Transplant 2003; 18 : 1272-1280.
11. Pieczenik SR, Neustadt J . Mitochondrial dysfunction and molecular pathways of disease . Exp Mol Pathol 2007; 83 : 84-92.
12. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J . Free radicals and antioxidants in normal physiological functions and human disease . Int J Biochem Cell Biol 2007; 39 : 44-84.
13. Droge W . Free radicals in the physiological control of cell function . Physiol Rev 2002; 82 : 47-95.
14. Finkel T . Oxidant signals and oxidative stress . Curr Opin Cell Biol 2003; 15 : 247-254.
15. Nathan C . Specifi city of a third kind: Reactive oxygen and nitrogen intermediates in cell signalling . J Clin Invest 2003; 111 : 769-778.
16. Bedard K, Krause KH . The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology . Physiol Rev 2007; 87 : 245-313.
17. Kau N, Forman HJ . Reactive oxygen species in physiology and toxicology: From lipid peroxidation to transcriptional activation . In: Rhodes CR (ed.). Toxicology of the Human Environment: The Critical Role of Free Radicals . New York, NY: Taylor and Francis; 2000. pp. 310- 335.
18. Palmer RMJ, Ferrige AG, Moncada S . Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor . Nat 1987; 327: 524- 526.
19. Nordberg J, Arner ESJ . Reactive oxygen species, antioxidants, and the mammalian thioredoxin system . Free Radic Biol Med 2001; 31 : 1287-1312.
20. Dalton TP, Shertzer HG, Puga A . Regulation of gene expression by reactive oxygen . Annu Rev of Pharmacol and Toxicol 1999; 39 : 67-101.
21. Chen ZH, Niki E . Two faces of lipid peroxidation products: The " Yin and Yang " principles of oxidative stress . J Exp Integr Med 2011; 1 : 215-219.
22. Seis H . Oxidative stress: Introductory remarks . In: Seis H (ed). Oxidative Stress. London: Academic Press; 1985. pp. 1-8.
23. Fearon IM, Faux SP . Oxidative stress and cardiovascular disease: Novel tools give (free) radical insight . J Mol Cell Cardiol 2009; 47: 372- 381.
24. Laksmi SVV, Padmaja G, Kuppusamy P, Kutala VK . Oxidative stress in cardiovascular disease . Indian J Biochem Biophys 2009; 46 : 421-440.
25. Elahi MM, Kong YX, Matata BM . Oxidative stress as a mediator of cardiovascular disease . Oxid Med Cell Longev 2009; 2 : 259-269.
26. Vallance P, Collier J, Moncada S . Eff ects of endotheliumderived nitric oxide on peripheral arteriolar tone in man . Lancet, 1989; 2 : 997-1000.
27. Vanhoutte PM . Endothelium and control of vascular tone . Hypertens 1989; 13 : 658-667.
28. Cai H, Harrison DG . Endothelial dysfunction in cardiovascular disease . The role of oxidant stress. Circ Res 2000; 87 : 840-844.
29. Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE . Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension . N Engl J Med 1990; 323 : 22-27.
30. Zorio E, Gilabert-Estell é s J, Espa ñ a F, Ram ó n LA, Cos í n R, Estellés A . Fibrinolysis: The key to new pathogenic mechanisms . Curr Med Chem 2008; 15 : 923-929.
31. Foncea R, Carvajal C, Almarza C, Leighton F . Endothelial cell oxidative stress and signal tansduction . Biol Res 2000; 33 : 89-96.
32. M ü nzel T, Sinning C, Post F, Warnholtz A, Schulz E . Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction . Ann Med 2008; 40 : 180-196.
33. Witte KK, Clark AL . Chronic heart failure and multiple micronutrient supplementation: Realistic hope or idealistic conjecture? Heart Fail Mon 2005; 4 : 123-129.
34. Nedeljkovic ZS, Gokce N, Loscalzo J . Mechanisms of oxidative stress and vascular dysfunction . Postgrad Med J 2003; 79 : 195-200.
35. Higashi Y, Noma K, Yoshizumi M, Kihara Y . Endothelial function and oxidative stress in cardiovascular diseases . Circul J 2009; 73 : 411-418.
36. Singh U, Jialal I . Oxidative stress and atherosclerosis . Pathophysiology, 2006; 13 : 129-142.
37. Chisolm, GM, Steinberg D . The oxidative modifi cation hypothesis of atherogenosis: An overview . Free Radic Biol Med2008; 28 : 1815-1826.
38. R, Keaney JF . Role of oxidative modifi cations in atherosclerosis . Physiological Review 2001; 84 : 1381-1478.
39. Montezano AC, Touyz RM . Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: A basic science update for the clinician . Can J Cardiol 2012; 28 : 288-295.
40. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, et al . Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats . Proc Natl Acad Sci U S A 1998; 95 : 4754-4759.
41. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M . Oxidative stress and mitochondrial dysfunction in atherosclerosis: Mitochondria-targeted antioxidants as potential therapy . Curr Med Chem 2009; 16: 4654- 4667.
42. Briones AM, Touyz RM . Oxidative stress and hypertension: Current concepts . Curr Hypertens Rep 2010; 12 : 135-142.
43. Hirata Y, Satanoka H . Hypertension and oxidative stress . J Jpn Med Assoc 2001; 124 : 1575-1579.
44. Lassague B, Clempus RE . Vascular NAD(P)H oxidases: Specifi c features, expression, and regulation . Am J Physiol Regul Integr Comp Physiol 2003; 285: R277- 297.
45. Beg M, Gupta A, Khanna VN . Oxidative stress in essential hypertension and role of antioxidants . J Indian Acad Clin Med 2010; 11 : 287-293.
46. Paravicini TM, Touyz RM . Redox signalling in hypertension . Cardiovas Re 2006; 71: 247- 258.
47. Förstermann U . Nitric oxide and oxidative stress in vascular disease . Pflugers Arch-Eur J Physiol 2010; 459 : 923-939.
48. Nickenig G, Harrison DG . The AT1-type angiotensin receptor in oxidative stress ans atherogenesis . Circulation 2002; 105 : 393-396.
49. Zalba G, San Jose G, Moreno MU, Fortuno MA, Beaumont FJ, Diez J . Oxidative stress in arterial hypertension; role of NAD(P) H oxidase. Hypertension, 2001; 38: 1395- 1399.
50. Wassmann S, Laufs U, B ä umer AT, M ü ller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression in Rac1 GTPase . Mol Pharmacol 2001; 59 : 646-654.
51. Touyz RM, Yao G, Schiff rin EL . c-Src induces phosphorylation and translocation of p47phox: Role in superoxide generation by angiotensin II in human vascular smooth muscle cells . Arterioscler Thromb Vasc Biol 2003; 23 : 981-987.
52. Suh YA, Arnold RS, Lassègue B, Shi J, Xu X, Sorescu D, et al . Cell transformation by the superoxide-generating oxidase Mox1 . Nature 1999; 401 : 459-461.
53. Madamanchi NR, Vendrov A, Runge MS . Oxidative stress and vascular disease . Arterioscler Thromb Vasc Biol 2005; 25 : 29-38.
54. Sorescu D, Griendling KK . Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure . Congest Heart Fail 2002; 8 : 132-140.
55. Hamilton CA, Miller WH, Al-Benna S, Brosnan MJ, Drummond RD, McBride MW, et al. Strategies to reduce oxidative stress in cardiovascular disease . Clini Sci 2004; 106 : 219-234.
56. Mallat Z, Phi M, Chatel D, Maclouf J, Tedgui A . in pericardial fl uid of patients Elevated level of 8-iso-prostaglandin F2 with heart failure: A potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circ 1998; 97: 1536- 1539.
57. Murdoch CE, Zhang M, Cave AC, Shah AM . NAD(P)H oxidase-dependent redox signaling in cardiac hypertrophy, remodeling and failure. Cardiovas Res 2006; 71: 208- 215.
58. Giordano FJ . Oxygen, oxidative stress, hypoxia, and heart failure . J Clin Inves 2005; 115 : 500-508.
59. Victor VM, Apostolova N, Herance R . Oxidative stress and mitochondrial dysfunction in atherosclerosis: Mitochondriatargeted antioxidants as potential therapy . Curr Med Chem 2009; 16 : 4654-4667.
60. Viel EC, Benkirane K, Javeshghani D . Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats . Am J Physiol Heart circ Physio 2008; 295: H281- H288.
61. Tsutsui H, Kinugawa S, Matsushima S . Mitochondrial oxidative stress and dysfunction in myocardial remodelling . Cardiovas Res 2009; 81 : 449-456.
62. Siwik DA, Pagano PJ, Colucci WS . Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fi broblasts . Am J Physiol Cell Physiol 2001; 280 : C53-C60.
63. Klebl BM, Ayoub AT, Pette D . Protein oxidation, tyrosine nitration, and inactivation of sarcoplasmic reticulum Ca 2 -ATPase in low-frequency stimulated rabbit muscle . FEBS Letters 1998; 422 : 381-384.
64. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R . Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 2000; 87: 241- 247.
65. Ahmed Z, Tang WHW . Pharmacologic strategies to target oxidative stress in heart failure . Curr Heart Fail Rep 2012; 9 : 14-22.
66. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFayden J, et al . Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians ' Health Study II randomized controlled trial . JAMA 2008; 300 : 2123-2133.
67. Forstermann U . Janus-faced role of endothelial NO synthase in vascular disease: Uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal . Biol Chem 2006; 387 : 1521-1533.
68. Yasunari K, Maeda K, Minami M, Yoshikawa J . HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress . Arterioscler Thromb Vasc Biol2001; 21 : 937-942.
69. Delbose S, Cristol JP, Descomps B, Mimran A, Jover B . Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress . Hypertens 2002; 40 : 142-147.
70. Hostetter TH . Chronic kidney disease predicts cardiovascular disease . New Engl J Med 2004; 351 : 1344-1346
71. Beaglehole R, Ebrahim S, Reddy S, Vo û te J, Leeder S . Chronic Disease Action Group . Prevention of chronic diseases: A call to action. Lancet 2007; 370 : 2152-2157.
72. Getz GS, Reardon CA . Nutrition and cardiovascular disease . Arterioscler Thromb Vasc Biol 2007; 27 : 2499-2506.
73. Ross R . The pathogenesis of atherosclerosis: A perspective for the 1990s . Nat 1993; 362 : 801-809.
74. Ross R . Atherosclerosis-an inflammatory disease . New Engl J Med 1999; 340: 115- 126.
75. Red ó n J, Cea-Calvo L, Lozano JV, Fern á ndez-P é rez C, Navarro J, Bonet A, et al. Kidney function and cardiovascular disease in the hypertensive population: The ERIC-HTA study . Journal of Hypertens 2006 ; 2 : 663-669
76. Vaziri ND . Oxidative stress in uremia: Nature, mechanisms, and potential consequences . Semin Nephrol 2004; 24 : 469-473.
77. Agarwal R . Chronic kidney disease is associated with oxidative stress independent of hypertension . Clin Nephrol 2004; 61 : 377-383.
78. Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei BL, van Tits LJ, et al . Oxidative stress in patients with endstage renal disease prior to the start of renal replacement therapy . Nephron Clin Pract 2004; 98: C3- c7.
79. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, et al . Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure . J Immunol 1998; 161 : 2524-2532
80. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, et al . Plasma F-isoprostane levels are elevated in chronic hemodialysis patients . Clin Nephrol2002; 58 : 190-197.
81. Salomon RG, Batyreva E, Kaur K, Sprecher DL, Schreiber MJ, Crabb JW, et al. Isolevuglandinprotein adducts in humans: Products of free radical- induced lipid oxidation through the isoprostane pathway . Biochimica et Biophysica Acta 2000; 1485: 2 25- 2 35.
82. Puchades Montesa MJ, Gonz á lez Rico MA, Sol í s Salguero MA, Torregrosa Maicas I, Tormos Muñoz MC, Saez Tormo G, et al. Study of oxidative stress in advanced kidney disease . Nefrologia 29: 464- 473.
83. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, et al . The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine . Am J Kidney Dis 2006; 47 : 42-50.
84. Cottone S, MulèG, Guarneri M, Palermo A, Lorito MC, Riccobene R, et al . Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients . Nephrol Dial Transplant 2009; 24 : 497-503.
85. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD . Am J Kidney Dis 2006; 48 : 752-760.
86. Gosmanova EO, Le NA . Cardiovascular Complications in CKD Patients: Role of Oxidative Stress. SAGE-Hindawi Access to Research Cardiology Research and Practice Volume, Article ID 156326, 8 pages
87. Himmelfarb J, McMenamin E, McMonagle E . Plasma aminothiol oxidation in chronic hemodialysis patients . Kidney Int 2002; 61 : 705-716.
88. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thé venin M, Jaudon MC, Zingraff J, et al . Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure . Free Radic Biol Med 1996; 21 : 845-853.
89. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thé venin M, Jaudon MC, Zingraff J, et al . Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure . Free Radic Biol Med 1996; 21 : 845-853.
90. Kim HJ, Vaziri ND . Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure . Am Physiol Renal Physiol 2010; 298 : F662-671.
91. Miyata T, van Ypersele C, Kurokawa K, Baynes JW . Alterations in nonenzymatic biochemistry in uremia: Origin and signifi cance of " carbonyl-stress " in long-term uremic complications . Kidney Int 1999; 55 : 389-399.
92. Vaziri ND, Pahl MV, Crum A, Norris K . Eff ect of uremia on structure and function of immune system . J Renal Nutr 2012; 22 : 149-156.
93. Tsakolos ND, Theoharides THC, Hendler ED, Goffi net J, Dwyer JM, Whisler RL . Immune defect in chronic renal impairment: Evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on hemodialysis. Clin Exp Immunol 1986; 63: 218- 227.
94. Robinson MK, Rodrick ML, Jacobs DO, Rounds JD, Collins KH, Saporoschetz IB, et al . Glutathione depletion in rats impairs T-cell and macrophage immune function . Arch Surg 1993; 128 : 29-34.
95. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C . Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns . Proc Natl Acad Sci 1998; 95 : 3071-3076.
96. Charra B . Fluid balance, dry weight, and blood pressure in dialysis . Hemodial Int 2007; 11 : 21-31.
97. Depner TA . Uremic toxicity: Urea and beyond . Semin Dial 2001; 14 : 246-251.
98. Di Micco L, Marzocco S, Sirico ML, Torraca S, Di Iorio B . Does daily dialysis improve hypertension in chronic haemodialysis patients? . Current Hypertension Review 2012; 8 : 291-295.
99. Akahoshi T, Kobayashi N, Hosaka S, Sekiyama N, Wada C, Kondo H . In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure . Nephrol Dial Transplant 1995; 10 : 2244-2249.
100. Nakanishi I, Moutabarrik A, Okada N, Kitamura E, Hayashi A, Syouji T, et al. Interleukin-8 in chronic renal failure and dialysis patients . Nephrol Dial Transplant 1994; 9 : 1435-1442.
101. Becker BN, Himmelfarb J, Henrich WL, Hakim RM . Reassessing the cardiac risk profi le in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors . J Am Soc Nephrol 1997; 8 : 475-486.
102. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J . Imbalance of oxidants and antioxidants in haemodialysis patients . Blood Purif 1999; 17 : 99-106.
103. Descamps-Latscha B, Herbelin A . Long-term dialysis and cellular immunity: A critical survey . Kidney Int Suppl 1993; 41 : S135-S142.
104. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM . The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia . Kidney Int 2002; 62 : 1524-1538.
105. Ritz E, Deppisch R, Stier E, H ä nsch G . Atherogenesis and cardiac death: Are they related to dialysis procedure and biocompatibility? Nephrol Dial Transplant 1994; 9 : S165-S172.
106. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A . Oxidative stress and inflammation: Implications in uremia and hemodialysis . Clin Biochem 2011; 44 : 1189-1198
107. Autore G, Marzocco S, Sorrentino R, Mirone V, synthesis by methylguanidine, Baydoun A, Pinto A . In vitro and in vivo TNF an uremic catabolyte . Life Sci 1999; 65 : 121-127.
108. Marzocco S, Di Paola R, Serraino I, Sorrentino R, Meli R, Mattaceraso G, et al. Eff ect of methylguanidine in carrageenan- induced acute inflammation in the rats . Eur J Pharmacol 2004; 484 : 341-350.
109. Marzocco S, Di Paola R, Genovese T, Sorrentino R, Britti D, Scollo G, et al . Methylguanidine reduces the development of non septic shock induced by zymosan in mice . Life Sci 2004; 75 : 1417-33.
110. Marzocco S, Popolo A, Bianco G, Pinto A, Autore G . Pro-apoptotic eff ect of methylguanidine on hydrogen peroxide- treated rat glioma cell line . Neurochem Int2010; 57 : 518-24.
111. Tanaka H, Komaba H, Koizumi M, Kakuta T, Fukagawa M . Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral bone disorder . J Renal Nutr 2012; 22 : 98-101.
112. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B . Elevated circulating levels of interleukin-6 in patients with chronic renal failure . Kidney Int 1991; 39 : 954-960.
113. Kiss I . The uremic toxin, indoxyl sulphate, signifi es cardiorenal risk and intestinal-renal relationship . Orv Hetil 2011; 152 : 1724-30.
114. Iida S, Kohno K, Yoshimura J, Ueda S, Usui M, Miyazaki H, et al . Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure . Clin Exp Nephrol 2006; 10 : 262-7.
115. Patel KP, Luo FJ, Plummer NS, Hostetter TH, Meyer TW . The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol 2012; 982- 8.
116. Marzocco S, Dal Piaz F, Di Micco L, Torraca S, Sirico ML, Tartaglia D, et al . Very Low Protein Diet Reduces Indoxyl Sulfate Levels in Chronic Kidney Disease . Blood Purifi c 2013; 35: 196- 201. Kao
117. . Kao MP, Ang DSC, Pall A, Struthers AD . Oxidative stress in renal dysfunction: Mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 2010; 24: 1- 8.
118. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B . Erythropoietin and oxidative stress in haemodyalisis: Benefi cial eff ects of Vitamin E supplementation . Nephrol Dial Transplant 1997; 12 : 2312-2317.
119. Targn DC, Huang TP, Chen TW, Yang WC . Erythropoietin hyporesponsiveness: From iron defi ciency to iron overload . Kidney Int Supp 1999; 69 : S107-S118.
120. Wratten ML, Navino C, Tetta C, Verzetti G . Haemolipodialysis . Blood Purif 1999; 17 : 127-33.
121. Iglesias P, Selgas R, Romero S, D í ez JJ . Selenium and kidney disease . J Nephrol. 2012.